Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.

[1]  M. Fontana,et al.  Cardiac Amyloidosis: Updates in Imaging , 2019, Current Cardiology Reports.

[2]  A. Jaffe,et al.  Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. , 2019, Blood.

[3]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[4]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[5]  R. Falk,et al.  ‘A new staging system for cardiac transthyretin amyloidosis’: is it already on the verge of obsolescence? , 2018, European heart journal.

[6]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[7]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[8]  M. Emdin,et al.  Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis , 2019, Journal of Nuclear Cardiology.

[9]  C. Rapezzi,et al.  Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.

[10]  S. Frusconi,et al.  Different NT-proBNP circulating levels for different types of cardiac amyloidosis , 2016, Journal of cardiovascular medicine.

[11]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[12]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[13]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[14]  G. Gensini,et al.  Echocardiographic and Biohumoral Characteristics in Patients With AL and TTR Amyloidosis at Diagnosis , 2015, Clinical cardiology.

[15]  W. Tang,et al.  A combined-biomarker approach to clinical phenotyping renal dysfunction in heart failure. , 2014, Journal of cardiac failure.

[16]  S. Solomon,et al.  Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis , 2014, Circulation.

[17]  M. Maurer,et al.  99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses , 2013, Circulation. Cardiovascular imaging.

[18]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Doughty,et al.  Renal Dysfunction in Heart Failure Patients with Preserved versus Reduced Ejection Fraction: Impact of the New CKD-EPI Formula , 2012 .

[20]  L. Padeletti,et al.  Cardiac amyloidosis: the heart of the matter , 2013, Internal and Emergency Medicine.

[21]  S. Kimmel,et al.  Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials , 2011, European journal of heart failure.

[22]  S. Gottlieb,et al.  Cardiorenal Syndrome: New Perspectives , 2010, Circulation.

[23]  R. Falk,et al.  Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway , 2010, Proceedings of the National Academy of Sciences.

[24]  M. Kroll,et al.  The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. , 2010, American journal of clinical pathology.

[25]  Rinaldo Bellomo,et al.  Cardiorenal syndrome. , 2008, Journal of the American College of Cardiology.

[26]  V. Hasselblad,et al.  Cardiorenal interactions: insights from the ESCAPE trial. , 2008, Journal of the American College of Cardiology.

[27]  Y. Pinto,et al.  Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? , 2006, Journal of the American College of Cardiology.

[28]  R. Fitzgerald,et al.  Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. , 2006, American journal of clinical pathology.

[29]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[30]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Therneau,et al.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. , 2004, Blood.

[32]  M. Skinner,et al.  Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress , 2004, Circulation research.

[33]  T. Therneau,et al.  Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins , 2003, The Lancet.